SBEV news

Endovia Health Sciences, formerly Splash Beverage, received Investigational New Animal Drug (INAD) status for its veterinary cancer pain treatment CannEpil, marking its first regulatory milestone under the Lupvindol collaboration.

Splash Beverage Group, Inc. is transforming into a cannabinoid-based health sciences platform and will trade under the new ticker EDVA effective Monday, August 24, 2026.

Splash Beverage reported a strengthened balance sheet and expanded its pharmaceutical cannabinoids pipeline via licensing deals, signaling a shift towards Endovia Health Sciences.

Splash Beverage Group partners with Lupvindol Biosciences to advance CannEpil for companion-animal oncology and pain through FDA veterinary pathways, retaining ownership of resulting data and IP.

Splash Beverage Group and Argent Biopharma amended their agreement to expand the field to veterinary purposes and set different royalty rates of 15% for human and 10% for veterinary sales. This strategic move positions the company for potential new market segments in the healthcare industry.

The company settled approximately $3.3 million in legacy liabilities and approved a 1-for-4 reverse stock split. This move is intended to bolster balance sheet strength and ensure continued compliance with NYSE American listing requirements.

Splash Beverage Group received approval from NYSE American to regain compliance through January 2027, avoiding a potential delisting. This continued listing status allows the company to execute its strategic transformation into a cannabinoid wellness platform while meeting exchange requirements.

Splash Beverage Group entered a global licensing deal for the epilepsy drug CannEpil and received $1 million in funding. This acquisition targets patients with drug-resistant epilepsy and leverages existing international commercialization pathways for U.S. development.

Splash Beverage Group completed a strategic investment in Avicanna Inc., a commercial-stage cannabinoid-based biopharmaceutical company, as part of its transformation into a cannabinoid healthcare platform. The investment signals Splash's strategic pivot toward regulated medical cannabinoid products…

Splash Beverage submitted a compliance plan to NYSE American on May 28, 2026 to address stockholders' equity concerns, with potential cure period through January 29, 2027. The company's non-binding letter of intent with Medterra CBD expired on May 4, 2026, but management continues evaluating multipl…